Portal de Periódicos da CAPES

The Potential for microRNA Therapeutics and Clinical Research

2019; Frontiers Media; Volume: 10; Linguagem: Inglês

10.3389/fgene.2019.00478

1664-8021

Johora Hanna, Gazi S. Hossain, Jannet Kocerha,

RNA modifications and cancer

As FDA approved small RNA drugs start to enter clinical medicine, ongoing studies for the microRNA (miRNA) class of small RNAs expand its preclinical and clinical research applications. A growing number of reports suggest a significant utility of miRNAs as biomarkers for pathogenic conditions, modulators of drug resistance, and/or as drugs for medical intervention in almost all human health conditions. The pleiotropic nature of this class of non protein-coding RNAs make them particularly attractive drug targets for diseases with a multifactorial origin and no current effective treatments. As candidate miRNAs begin to proceed toward initiation and completion of potential phase 3 and 4 trials in the future, the landscape of both diagnostic and interventional medicine will arguably continue to evolve. In this mini-review, we discuss miRNA drug discovery development and their current status in clinical trials.